The GLP-1 Receptor Agonist Liraglutide Attenuates Atherosclerotic Lesion Development and Potentially Enhances Plaque Stability in an ApoE-/- Mouse Model

被引：0
|
作者：
Simpson, Richard W.
Gaspari, Tracey
Welungoda, Iresha
Widdop, Robert E.
Knudsen, Lotte B.
Dear, Anthony E.
机构：
来源：
DIABETES | 2012年 / 61卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1896-P
引用
收藏
页码：A486 / A486
页数：1
相关论文
共 50 条
  • [41] Liraglutide, a Glucagon-like Peptide-1 Receptor Agonist, Attenuates Development of Cardiac Allograft Vasculopathy in a Murine Heart Transplant Model
    Wang, ZhiMin
    Wang, Mengjun
    Hu, Xiaofan
    Li, Yakun
    Ma, DongXia
    Li, ShangLin
    Zhao, GuangYuan
    Xie, Yanan
    Shu, Yanwen
    Yang, Jun
    TRANSPLANTATION, 2019, 103 (03) : 502 - 511
  • [42] The GLP-1/GIP dual-receptor agonist DA5-CH inhibits the NF-κB inflammatory pathway in the MPTP mouse model of Parkinson's disease more effectively than the GLP-1 single-receptor agonist NLY01
    Lv, MiaoJun
    Xue, GuoFang
    Cheng, HuiFeng
    Meng, PengFei
    Lian, Xia
    Holscher, Christian
    Li, DongFang
    BRAIN AND BEHAVIOR, 2021, 11 (08):
  • [43] LACK OF ANGIOTENSIN II TYPE 1 RECEPTOR IN BONE MARROW-DERIVED CELLS INHIBITS VULNERABLE ATHEROSCLEROTIC PLAQUE DEVELOPMENT IN 2-KIDNEY, 1-CLIP APOE-/- MICE
    Pellegrin, Maxime
    Bouzourene, Karima
    Aubert, Jean-Francois
    Nahimana, Aimable
    Duchosal, Michel A.
    Mazzolai, Lucia
    ATHEROSCLEROSIS, 2017, 263 : E14 - E14
  • [44] GLP-1/glucagon dual receptor agonist ALT-801 is superior to semaglutide in improving NASH endpoints in a biopsy-confirmed DIO mouse model
    Nestor, John
    Rigbolt, Kristoffer
    Feigh, Michael
    Parkes, David
    Harris, M. Scott
    JOURNAL OF HEPATOLOGY, 2020, 73 : S456 - S456
  • [45] Novel Cannabinoid Receptor 1 Inverse Agonist CRB-913 Enhances Efficacy of Tirzepatide, Semaglutide, and Liraglutide in the Diet-induced Obesity Mouse Model
    Morningstar, Marshall
    Kolodziej, Andrew
    Ferreira, Suzie
    Blumen, Tracy
    Brake, Rachael
    Cohen, Yuval
    OBESITY, 2023, 31 : 51 - 51
  • [46] A GLP-1/GIP Dual Receptor Agonist DA4-JC Effectively Attenuates Cognitive Impairment and Pathology in the APP/PS1/Tau Model of Alzheimer's Disease
    Cai, Hong-Yan
    Yang, Dan
    Qiao, Jing
    Yang, Jun-Ting
    Wang, Zhao-Jun
    Wu, Mei-Na
    Qi, Jin-Shun
    Hoelscher, Christian
    JOURNAL OF ALZHEIMERS DISEASE, 2021, 83 (02) : 799 - 818
  • [47] PT320, a Sustained-Release GLP-1 Receptor Agonist, Ameliorates L-DOPA-Induced Dyskinesia in a Mouse Model of Parkinson's Disease
    Kuo, Tung-Tai
    Chen, Yuan-Hao
    Wang, Vicki
    Huang, Eagle Yi-Kung
    Ma, Kuo-Hsing
    Greig, Nigel H. H.
    Jung, Jin
    Choi, Ho-, II
    Olson, Lars
    Hoffer, Barry J. J.
    Tseng, Kuan-Yin
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (05)
  • [48] Anti-inflammatory and anti-fibrotic effects of icosabutate as mono- or combination therapy with a GLP-1 receptor agonist, a FXR agonist or an ACC inhibitor in a dietary mouse model of progressive fibrosis
    Fraser, David A.
    Nohr-Meldgaard, Jacob
    Skjaeret, Tore
    Veidal, Sanne
    Feigh, Michael
    Harrison, Stephen
    JOURNAL OF HEPATOLOGY, 2021, 75 : S622 - S623
  • [49] Synergistic activity of GLP-1 peptide analog XW003 and the long-lasting GIP receptor agonist XW017 in a diet induced obese mouse model
    Wu, Xinle
    Zou, Haixia
    Wang, Bin
    Zhu, Rui
    Li, Yan
    Guo, Wanjun
    Jones, Catherine
    Fenaux, Martijn
    JOURNAL OF HEPATOLOGY, 2022, 77 : S726 - S726
  • [50] A GLP-1/GIP Dual Receptor Agonist DA4-JC Effectively Attenuates Cognitive Impairment and Pathology in the APP/PS1/Tau Model of Alzheimer's Disease (vol 83, pg 799, 2021)
    Cai, Hong-Yan
    Yang, Dan
    Qiao, Jing
    Yang, Jun-Ting
    Wang, Zhao-Jun
    Wu, Mei-Na
    Qi, Jin-Shun
    Holscher, Christian
    JOURNAL OF ALZHEIMERS DISEASE, 2023, 94 (04) : 1617 - 1618
12345